|
Specialty:
Medical Oncology
Present Titles and Affiliation:
Vice Chair of Lung Cancer Research Center, Sun Yat-Sen
University
Vice Chair of Department of Medical Oncology, Sun Yat-Sen University
Cancer Center
Contact Information:
Address： 651 Dongfeng Road East, Guangzhou 510060, P.R.
China
Tel & Fax： 86-20-8734-3458；86-20-87343365 (Fax)
E-mail： zhangli@sysucc.org.cn
Research interest:
Dr Zhang’s research is focused on developing molecular, prognostic
and therapeutic approaches to improve the care for patients with
lung cancer, colorectal cancer and nasopharyngeal carcinoma. His
research interest also includes supportive care such as therapy of
cancer induced anemia (CIA) and treatment of bone metastases with
bisphosphonate. He is currently a member of the NCCN Clinical
Practice Guidelines in Oncology™ (Chinese Version) Lung Cancer,
Colon/Rectal Cancer and Head and Neck Cancer Panel. He has been
extensively involved in many Phase I/II studies of novel anticancer
agents and international phase III trials. Now, he is also a GLOBE
principle investigator (PI) and steering committee member of several
randomized phase III clinical trials.
Dr Zhang has published more than 100 clinical research papers in
peer review journals such as Journal of Clinical Oncology, Lancet
Oncology, Cancer, Cancer Gene Therapy, Journal Thoracic Oncology,
Lung Cancer, Cancer Chemotherapy and Pharmacology, Oncology,
Clinical Lung Cancer and Medical Oncology.
Dr Zhang also presented abstracts to many major congresses like ASCO,
AACR, WCLC, ESMO meetings. Besides a heavy patient caseload in his
department, Dr. Zhang is a frequent lecturer in many domestic and
international congresses, like Chinese Society for Clinical Oncology
(CSCO), Chinese Anti-Cancer Association (CACA), Chinese Conference
on Medical Oncology (CCMO) and Chinese Society of Lung Cancer annual
meeting, WCLC, APLCC. He now works as a senior consultant at the
Centre of Drug Evaluation (CDE) of State Food and Drug
Administration (SFDA) in China. Dr Zhang is the drafter of “SFDA
guidance for industry: clinical trials for the approval of
anticancer drugs and biologicals (Second Version, 2006).”
Education and Training:
2001.3-2002.3: Visiting fellow (Medical Oncology)
MD Anderson Cancer Center
Houston, TX. USA
1998.1-1998.1: Visiting fellow (Medical Oncology)
Fox Chase Cancer Center
Philadelphia, PA, USA
1996.9-1996.10: Visiting fellow (GCP, Good Clinical Practice)
Institute Gustave Roussy (IGR)
Paris, France
1991.9-1997.9 Attending Physician
Department of Medical Oncology,
Tumor Hospital, Sun Yat-Sen University of Medical Sciences
1988.9-1991.8: Master of Clinical Oncology
Sun Yat-Sen University Cancer center
Guangzhou, P.R.China
1986.8-1991.8: Resident
Department of Medical Oncology,
Tumor Hospital, Sun Yat-Sen University of Medical Sciences
1980.9-1986.7: Bachelor of Medicine
Sun Yat-Sen University of Medical Sciences
Gangzhou, P.R.China
Board Certification:
1991: Clinical Oncology Board Certification
1986: Internal Medicine Board Certification
Experience/Service
Academic Appointments
2005-present: Professor and Vice Chair of the Department of Medical
Oncology, Sun Yat-Sen University Cancer Center
1997-2005: Associate Professor and Vice Chair of the Department of
Medical Oncology, Sun Yat-Sen University Cancer Center
Other Appointments/Responsibilities in
Hospital and University:
2006-Present: Ethical Committee Member of Sun Yat-Sen
University
2007-Present: Scientific Committee Member of Sun Yat-Sen University
Cancer
2007-Present: Medical Affair Committee Member of Sun Yat-Sen
University Cancer Center
2007-Present: Infection Disease Committee Member of Sun Yat-Sen
University Cancer Center
Memberships in Professional Societies:
Chinese Association of Medicine (CAM), 1997-present
Chinese Anti-Cancer Association (CACA), 1997-present
Chinese Society of Clinical Oncology (CSCO), 1997-present
American Society of Clinical Oncology (ASCO), 2004-present
International Association for the Study of Lung Cancer (IASLC),
2005-present European Society for Medical Oncology (ESMO),
2007-present
Editorships and Editorial Board:
Chinese Journal of Clinical Oncology, 2001-present
Chinese Journal of Cancer, 2001-present
Asia-Pacific Journal of Clinical Oncology (APJCO), 2005-2008
Chinese Journal of Tuberculosis and Respiratory Diseases,
2007-present
Journal of Clinical Oncology (Chinese Version), 2007-present
Chinese Journal of Lung Cancer, 2008-present
Lung Cancer (Chinese Version), 2008-present
Chinese Journal of Cancer Research (English Version), 2010-present
Cancer Research on Prevention and Treatment, 2010-present
Clinical Lung Cancer, 2010-present
Thoracic Cancer, 2010-present
Editor of Clinical Lung Cancer Chinese Edition, 2010-present
The Chinese-German Journal of Clinical Oncology, 2010-present
Oncology Progression, 2010-present
Manuscript reviewer:
Journal of Thoracic Oncology, 2007-present
New Medicine, 2007-present
The Chinese-German Journal of Clinical Oncology, 2008-2010
Selected Publications:
1. Li Zhang, Chong Zhao, Pei-Jian Peng, Li-Xia Lu, Pei-Yu Huang, Fei
Han, and Shao-Xiong Wu: Preliminary Results of Randomized Phase III
Clinical Study Comparing Standard Radiotherapy With or Without
Weekly Oxaliplatin in Treatment of Locoregionally Advanced
Nasopharyngeal Carcinoma. Journal of Clinical Oncology 2005; Vol
23(33): 8461-8468
2. Zhang L, Hou X, Lu S, et al. Predictive significance of bone
sialoprotein and osteopontin for bone metastases in resected Chinese
non-small-cell lung cancer patients: A large cohort retrospective
study. Lung Cancer 2010, Jan;67(1):114-9
3. Xue Hou, Chong Zhao, Ying Guo, …Li Zhang*. Different Clinical
Significance of Pre- and Post-treatment Plasma Epsteine Barr Virus
DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy.
Clinical Oncology 2010 [Epub ahead of print]
4. Li Zhang, Chong Zhao, Bijesh Ghimire, … Ying Guo*, Yi-Jun Huang*,
Zhong-Zhen Guan：The Role of Concurrent Chemoradiotherapy in the
Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma among
Endemic Population: A Meta- analysis of the Phase III Randomized
Trials. BMC Cancer 2010．Vol 10:558
5. Zhao YY, Li S, Zhang Y, … Zhang L*. The relationship between drug
exposure and clinical outcomes of non-small cell lung cancer
patients treated with gefitinib. Med Oncol. 2010 May 11. [Epub ahead
of print]
6. Wang F, Zhang Y, Zhao H, … Zhang L*. Validation of a clinical
prognostic model in Chinese patients with metastatic and advanced
pretreated non-small cell lung cancer treated with gefitinib. Med
Oncol. 2010 Mar 4. [Epub ahead of print]
7. Xu F, Li S, Li XL, …Zhang L*. Phase I and biodistribution study
of recombinant adenovirus vector-mediated herpes simplex virus
thymidine kinase gene and ganciclovir administration in patients
with head and neck cancer and other malignant tumors. Cancer Gene
Therapy 2009; Vol 16:723-730
8. Zhang L, Zhang Y，, …Guan ZZ*. Phase II clinical study of
gemcitabine in the treatment of patients with advanced
nasopharyngeal carcinoma after the failure of platinum-based
chemotherapy. Cancer Chemother Pharmacol.2008；61(1):33-8.
9. Tony Mok, Yi-Long Wu, Chong-Jen Yu, Caicun Zhou, Yuh-Min Chen, Li
Zhang, …Jin-Soo Lee: Randomized, Placebo-controlled, Phase II Study
of Sequential Erlotinib and Chemotherapy As First-Line Treatment for
Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology
2009; Vol 27:5080-5087
10. Roy S Herbst, Yan Sun, Wilfried EE Eberhardt, Paul Germonpré,
Nagahiro Saijo, Caichun Zhou, Jie Wang, Longyun Li, Fairooz
Kabbinavar, Yukito Ichinose, Shukui Qin, Li Zhang, Bonne Biesma,
John V Heymach, Peter Langmuir, Sarah J Kennedy, Hiroomi Tada and
Bruce E Johnson. Vandetanib plus docetaxel versus docetaxel as
second-line treatment for patients with advanced non-small-cell lung
cancer: a randomised, double-blind phase III trial (ZODIAC). Lancet
Oncology 2010；Vol 11: 619–26
11. Tony Mok, Keunchil Park, Joseph Siu-kie Au, Caicun Zhou, Li
Zhang, Reury-Perng Perng, and Yi-long Wu: Efficacy and Safety of
Erlotinib in >1200 East/South-East Asian Patients with Advanced
Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2010; Vol
5: 1609–161
|
